Adverse effects of large doses of medroxyprogesterone (MPA) in idiopathic isosexual precocity.
D000311:Adrenal Glands / Q000378:metabolism; D000309:Adrenal Insufficiency / Q000139:chemically induced*; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D001827:Body Height; D001835:Body Weight; D001846:Bone Development / Q000187:drug effects; D002675:Child, Preschool; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006065:Gonadotropins, Pituitary / Q000378:metabolism; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D007018:Hypopituitarism / Q000139:chemically induced*; D007223:Infant; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000009:adverse effects*; D008797:Metyrapone; D010902:Pituitary Gland / Q000378:metabolism; D011629:Puberty, Precocious / Q000188:drug therapy*; D013739:Testosterone / Q000378:metabolism
D006065:Gonadotropins, Pituitary; D013739:Testosterone; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D013006:Growth Hormone; D008525:Medroxyprogesterone; D008797:Metyrapone